Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Autoimmune RORγt Program May Portend Change Of Direction For Vitae

Executive Summary

The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.

You may also be interested in...

Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?

Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.

March Gladness: Vitae Rebounds With Reassuring Data In Psoriasis

Vitae's first-in-class ROR gamma t inhibitor shows significant reduction of PASI scores with two doses tested in Phase IIa, and a solid safety profile, despite some liver enzyme increases with the higher dose.

Vitae Focused On Psoriasis After BI Terminates Collaboration

Now that its Alzheimer's partnership has ended and a diabetes tie-up is on uncertain ground, the computational drug-design firm has turned primarily to advancing psoriasis candidate VTP-43742.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts